Track Arcturus Therapeutics Holdings's long-term debt ($19M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2026), ARCT shows a long-term debt of $19M. That compares with $23M in the prior-year period — down 17.3% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ARCT's long-term debt is now $19M (was $23M) — a 17.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Arcturus Therapeutics Holdings is outperforming or lagging.
Tracking ARCT's long-term debt over time shows whether Arcturus Therapeutics Holdings is scaling, shrinking, or reshaping that part of the business. The current reading is $19M That compares with $23M in the prior-year period — down 17.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Arcturus Therapeutics Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $19M) with ownership activity and broader fundamentals.
Arcturus Therapeutics Holdings's long-term debt is $19M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.